Introduction
STS [9] . This trial enrolled patients with extremity STS (43.2%) and nonextremity STS (55.8%); 72.0% of patients underwent neoadjuvant therapy before their first resection, while 28.0% had undergone previous inadequate resection. The results showed that hyperthermia plus chemotherapy significantly increased local progression-free survival (hazard ratio [HR] = 0.58, P = 0.003) and disease-free survival (HR = 0.70, P = 0.011) compared to chemotherapy alone in both extremity and nonextremity STS. The surgical approaches did not differ between groups; they were almost identical (R0 resection, 53 and 42; R1 resection, 35 and 36; and R2 resection, 9 and 14 in the hyperthermia plus chemotherapy and chemotherapy alone groups, respectively), and similar numbers of patients required amputation (7 and 9 in the hyperthermia plus chemotherapy and chemotherapy alone groups, respectively).
In our institution, in addition to regional hyperthermia and chemotherapy, we simultaneously perform radiotherapy (radio-hyperthermo-chemotherapy [RHC]) as neoadjuvant therapy for high-grade STS. In this study, we assessed the oncologic outcomes of patients treated with RHC, limiting patients to those receiving neoadjuvant therapy, having extremity STS, and undergoing first resection, by comparing the RHC group to a nationwide database in Japan (Bone and Soft Tissue Tumor Registry [BSST] ) by propensity score matching. Furthermore, to assess the contribution of RHC to other neoadjuvant therapies (chemotherapy, radiotherapy, chemotherapy plus radiotherapy, or no neoadjuvant therapy), we compared oncologic outcome by extracting subgroups from whole BSTT group according to neoadjuvant therapy.
Methods Patients
From 1994 to 2013, RHC was performed in 150 patients with STS. Eligible patients were 15-70 years of age and had Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC) grade 2 or 3 extremity STS (low-grade sarcomas, such as dermatofibrosarcoma protuberans or well-differentiated liposarcoma, were not suitable for RHC). Tumors with diameters ≥5 cm were exclusively subjected to RHC, and tumors with diameters <5 cm with "tail signs [10] " or thick fascial enhancement extending from the tumor margin (e.g., myxofibrosarcoma and undifferentiated pleiomorphic sarcoma [UPS]) were also included in the RHC group. Exclusion criteria were: salvage treatment for recurrence or unplanned excision, metastasis at study initiation, chondro-osseous tumors, small round cell sarcoma, and no definitive surgery. All of the patients were fully informed about RHC therapy and potential associated adverse events and provided consent to participate. Anytime during the RHC procedure, patients had the latitude to change their treatment plans to alternative therapies. To minimize adverse events, patients were required to fulfill the following criteria: (1) white blood cell count, >3,000/μL; (2) platelet count, >7.5 × 10 4 /μL; (3) hemoglobin, >7.0 g/ dL; (4) creatinine clearance, >60 mL/min; (5) normal hepatic function; and (6) ejection fraction (EF), >60%.
RHC protocol
Prior to RHC therapy, angiography was performed to assess tumor blood flow, and a catheter was simultaneously inserted with a reservoir placed into the artery feeding the tumor (Fig. 1) . Anticancer drugs were intraarterially injected through this reservoir. Radiotherapy was initiated on day 1, and 2 Gy per fraction were delivered 20 times (on days 1-5, 8-12, 15-19 , and 22-26) for a total of 40 Gy. Following radiotherapy, thermotherapy was simultaneously initiated with intra-arterial injection of anticancer drugs. Cisplatin (CDDP, 100 mg/m 2 ) on days 1, 15, and 29 and pirarubicin (THP [a derivative of ADR], 30 mg/m 2 ) on days 8 and 22 were alternatively administered. The treatment interval was extended depending on patient status, and, if necessary, colony-stimulating factor was administered. Two weeks after RHC therapy was completed (day 43), additional neoadjuvant chemotherapy (IFO, 2 mg/m 2 ; VP-16, 100 mg/m 2 ; and THP, 30 mg/m 2 ; modified Rosen T-16 regimen [11] ) was administered intravenously.
For thermotherapy, an 8-MHz radiofrequency capacitive heating system (Thermotron RF-8: Yamamoto VINITA, Osaka, Japan) was used. Tumor temperature was monitored by inserting a hyperthermia needle into the tumor and inserting a thermocouple thermometer (0.64 mm, Thermotron CE-150, Yamamoto VINITA, Osaka, Japan) into the space. The treatment objective was to achieve a temperature of ≥42.5°C for 60 min (T42.5*60). Three categories were established based on the number of cycles in which T42.5*60 was achieved: poor hyperthermia, T42.5*60 was not achieved; mild hyperthermia, T42.5*60 was achieved in 1-3 cycles; and complete hyperthermia, T42.5*60 was achieved in 4-5 cycles [12] .
During the RHC treatment period, the efficacy of RHC was carefully monitored using several modalities, including dynamic magnetic resonance imaging (MRI), computed tomography (CT), Tl 201 -scintigraphy, and/or positron emission tomography (PET). If the response to RHC was a partial response (PR) or complete response (CR) in modified Response Evaluation Criteria in Solid Tumors (RECIST) or PET Response Criteria in Solid Tumors (PERCIST), marginal resection of the tumor was performed as minimally invasive surgery with preservation of neurovascular bundles. 
BSTT group
The BSTT is a nationwide organ-specific cancer registry for bone and soft tissue tumors in Japan [13] . The registry is funded by the Japanese Orthopaedic Association (JOA) and promoted by the National Cancer Center. A total of 89 JOA-certified hospitals specializing in musculoskeletal oncology are obliged to participate in this registry, but participation of other hospitals is voluntary. Annual reports include patient characteristics including basic patient data (sex, age, date of diagnosis, and treatment status at first visit [initial therapy or not]), tumor data (diagnosis, histologic details [malignant or benign disease and histologic grade for malignant tumors], tumor location, and data required for TNM staging [seventh edition AJCC staging]), surgical data (date of definitive surgery, type of surgery, reconstruction details, and additional surgery for complications), and information about neoadjuvant/adjuvant treatment (including chemotherapy, radiotherapy, and/or hyperthermia).
A second survey collects information on prognosis at 2, 5, and 10 years after initial registration. This includes information about several outcomes at the time of latest follow-up, such as local recurrence, distant metastasis, and oncologic outcome. The use of the BSTT database for the purpose of clinical research was initiated in 2014 after the approval of the Musculoskeletal Tumor Committee of the JOA.
Statistical analysis
The primary goal of this study was to validate the efficacy of the RHC by investigating oncologic outcomes (local control rate, defined as the time from surgery to local recurrence, and overall survival, defined as the time from surgery to death due to any cause) by comparing RHC and BSTT database. Secondary outcomes were to investigate each contribution of neoadjuvant therapy by comparing extracted subgroups from whole BSTT group according to neoadjuvant therapy.
Statistical parameters obtained from the BSTT database and our hospital included age, sex, tumor location, tumor size, tumor histology, tumor depth, neoadjuvant therapy (chemotherapy and/or radiotherapy), and adjuvant therapy (chemotherapy and/or radiotherapy). We also included information about surgery, such as usage of prosthesis, surgical margins, requirement for plastic surgery, infection, and delayed skin healing. Multivariate logistic regression analysis was performed to determine associations between these factors and RHC. Propensity scores were calculated using a logistic regression model by including the weights of the contributions of each patient's demographic data, except for information about neoadjuvant or adjuvant therapy. This was because all patients in the RHC group underwent both neoadjuvant chemotherapy + radiotherapy and 70% of patients in the RHC group underwent adjuvant chemotherapy so that the information about neoadjuvant or adjuvant therapy could strongly affect the fair matching. After calculation of propensity scores, we matched patients in both groups according to propensity score with a nearestneighbor algorithm, allowing a maximum tolerated difference between propensity scores of ≤30% of the propensity score. Considering the differences in the number of patients in each group, 5:1 propensity score matching was used for the whole BSTT group vs RHC group. Standardized group differences were calculated by Kaplan-Meier analysis. For the analysis of the risk factors for oncologic outcomes, hazard ratios were calculated using a Cox proportional hazards model. All statistical analyses were conducted using SPSS version 24 (IBM ® ). P-values <0.05 were considered statistically significant.
Ethics approval
This retrospective study has received the approval of the local committee of Nagoya City University Hospital and has been conducted in compliance with the guidelines of the Helsinki Declaration of 1975. Also, use of the BSTT database was approved by the Institutional Review Board of the JOA.
Results
From 2007 to 2013, 11,031 patients were registered in the BSTT database. Before matching, we excluded ineligible data from the database; 2,762 patients with some tumor types that had not coincidentally appeared in the RHC group, such as dedifferentiated liposarcoma and malignant peripheral nerve sheath tumor, were excluded. Next, 1,401 patients with nonextremity STS and 979 patients with unplanned excisions or recurrences were excluded; 2,715 patients with low-grade sarcoma, such as well-differentiated liposarcoma, solitary fibrous tumor, and low-grade myofibroblastic sarcoma, were excluded; 513 patients with metastasis during the initial period and 340 patients who had not undergone any surgery for primary tumors were excluded; and 417 patients for whom information was lacking were excluded. In summary, a total of 2,067 patients were eligible for this study (whole BSTT group; Fig. 2 ).
For the subgroup analysis, we assigned patients who underwent no neoadjuvant therapy, neoadjuvant chemotherapy, neoadjuvant radiotherapy, or neoadjuvant chemotherapy + radiotherapy into the BSTT-no neoadjuvant therapy subgroup, the BSTT-chemotherapy subgroup, the BSTT-radiotherapy subgroup, and the BSTT-chemotherapy + radiotherapy subgroup, respectively (Fig. 3) .
In addition, patients in the RHC group were excluded for the following reasons: salvage therapy for recurrence or unplanned excision (n = 26); trunk location (n = 4); metastasis at study initiation (n = 11); non-STS (n = 30); no definitive surgery (n = 8); and other (n = 11). Finally, 60 patients were included in the RHC group during the study period. An average of 4.58 cycles of RHC were given as neoadjuvant therapy. T42.5*60 was achieved in 68.3% of patients, and 48.3% of patients were considered to achieve complete hyperthermia (T42.5*60 = 4-5 cycles). However, 31.7% of patients achieved poor hyperthermia. Definitive surgery was performed with wide margins (60.0%), marginal margins (28.3%), and intralesional margins (11.7%). After surgery, based on patients status, the pathological analysis of margin, histological grade of tumor, or response to neoadjuvant therapy, 70.0% of patients received intravenous adjuvant chemotherapy with IFO, VP-16, and THP (up to 5 courses). Histological analysis revealed that 21.7% of patients had a complete response (total tumor necrosis) and 40% of patients had >90% necrosis; however, 13% of patients had a poor response (<50% necrosis). The mean follow-up period was 7.14 ± 4.84 years after definitive surgery.
In the RHC group, delayed skin healing after surgery (>2 weeks) occurred in 20 patients. Among these, eight patients required additional procedures (debridement, H. Aiba et al. Clinical Outcomes of RHC for STS surgical skin closure, or skin flap), but all cases were managed. One case of femoral head necrosis occurred, for which total hip arthroplasty was performed. Moreover, one case of prolonged fever of unknown origin occurred.
Whole BSTT group versus RHC group
First, the whole BSTT group was compared to the RHC group (Table 1) . Marginal tumor resection was more frequently performed in the RHC group (28.3% vs. 10.5%, RHC group vs. whole BSTT group, respectively; P < 0.001, Table 2 ). The 5-year overall survival rate was 78.3% and 81.2% in the whole BSTT and RHC groups, respectively (P = 0.326; Fig. 4A ). A statistically significant difference was observed in 5-year local control rates between the whole BSTT (85.1%) and RHC (97.7%) groups (P = 0.017, Next, patient characteristics in the whole BSTT group were adjusted using propensity scores (5:1 matching). The distribution of patients before and after adjustment is shown in Figure 5A and B. The 5-year overall survival rate in the BSTT group after adjustment was 79.3% (P = 0.532; Fig. 4C) . A statistically significant difference (P = 0.041) in the local control rate was observed: The 5-year local control rate in the BSTT group after adjustment was 87.1% (Fig. 4D) .
Subgroup analysis

BSTT-chemotherapy subgroup versus RHC group
To clarify the contribution of neoadjuvant therapy, we extracted data from patients in the whole BSTT group Figure 3 . Extraction of patients from whole BSTT group and its subgroups with propensity scores and matching to RHC group. *1. Propensity scores were calculated using a logistic regression model by including the weights of the contributions of each patient's demographic data, except for information about neoadjuvant or adjuvant therapy. *2. 5:1 propensity score matching was used for the whole BSTT group versus RHC group. *3. 5:1 propensity score matching was used for the BSTT-no neoadjuvant therapy subgroup versus RHC group. *4. 3:1 propensity score matching was used for the BSTT-no neoadjuvant therapy subgroup versus RHC group. *5. The numbers of patients were insufficient for matching analysis, so no data adjustment was performed. ASPS, alveolar soft part sarcoma; UPS, undifferentiated pleiomorphic sarcoma. Each P-value was compared to RHC group. *The numbers of patients with tumor under 5 cm in length of maximum diameter were 496 (24%), 65 (24%), and 12 (20%) (Whole BSTT group, BSTT group after adjustment, and RHC group, respectively). who received neoadjuvant chemotherapy (Fig. 3) . Neoadjuvant chemotherapy regimens were ADR + IFO (58%), mesna + ADR + IFO and dacarbazine (MAID, 11%), ADR + CDDP/IFO + VP-16 (9%), ADR + CDDP (4%), and others (26%). Before adjustment, the 5-year overall survival rate was 76.4% (Fig. 6A) , and the 5-year local control rate was 87.6% (Fig. 6B) . No statistically significant difference in overall survival (P = 0.376) was observed; however, the local control rate was slightly superior in the RHC group (P = 0.074).
Clinical Outcomes of RHC for STS
The distribution of patients before adjustment is shown in Fig. 7A and B; scores were not homogeneous in the two groups. Next, patient characteristics in the BSTTchemotherapy subgroup were adjusted using propensity scores (3:1 matching). The characteristics before and after matching are shown in Table 3 .
After adjustment, overall survival at 5 years was 77.6%; the difference between the BSTT-chemotherapy subgroup and RHC groups was not statistically significant (P = 0.532, Fig. 6C ). With respect to local control rate, the rate at 5 years was 85.7%. No statistically significant difference in local control rate was observed (P = 0.058, Fig. 6D ).
Comparison to other subgroups
Data from the no neoadjuvant therapy subgroup, radiotherapy subgroup, and radiotherapy + chemotherapy subgroup were extracted from the whole BSTT group to determine the contribution of each type of treatment on outcomes. The HRs between each subgroup and the RHC group were then calculated by log-rank analysis. The patient characteristics in the no neoadjuvant therapy group (n = 1,611) were adjusted using a 5:1 matched-pair analysis. Before adjustment, the HRs for overall survival rate and local control rate were 1.39 (95% CI: 0.72-2.67, P = 0.322) and 6.04 (95% CI: 1.48-24.74, P = 0.011), respectively. After adjustment, the HRs for overall survival rate and local control rate were 1.26 (95% CI: 0.56-2.82, P = 0.575) and 3.47 (95% CI: 0.79-15.35, P = 0.101), respectively. With respect to radiotherapy (n = 104) and radiotherapy plus chemotherapy (n = 44), the numbers of patients were insufficient for matching analysis, so no data adjustment was performed. The HRs for overall survival rate and local control rate were 1.00 (95% CI: 0.40-2.51, P = 0.994) and 5.58 (95% CI: 1.05-29.41, P = 0.044), respectively, in the radiotherapy group and were 1.04 (95% CI: 0.35-3.13, P = 0.940) and 3.65 (95% CI: 0.49-27.64, P = 0.205), respectively, in the radiotherapy plus chemotherapy group (Figs 8 and 9 ).
Discussion
Hyperthermia refers to heating tumors, tissues, or systems to temperatures of up to 42°C, either to sensitize tissue to conventional treatments or to induce tumor regression [14] . When combined with chemotherapy, hyperthermia is thought to enhance the antitumor activity of agents such as bleomycin [3] , CDDP [4] , and ADR [5, 6] by inhibiting their excretion and/or augmenting cancer cell sensitivity to these agents. In addition, both in vitro and in vivo studies have shown that hyperthermia has synergistic effects with radiotherapy. Hyperthermia compensates for the gaps in the cytotoxicity of radiotherapy by killing cells in S-phase; these cells are generally resistant to radiotherapy, but susceptible to hyperthermia [7] . Moreover, hypoxic cells, which are also impervious to radiotherapy, are vulnerable to hyperthermia because anaerobic metabolism creates a low-pH environment around hypoxic cells, which enhances thermal effects [8] . Our department has reported the direct effects of hyperthermia on STS in an in vitro/vivo study [15] . According to previous reports, the synergistic effects are most pronounced when hyperthermia is simultaneously performed with radiotherapy and chemotherapy. On the basis of this observation, we established a protocol for performing hyperthermia, chemotherapy, and radiotherapy as a concomitant trimodal therapy for STS.
In 2010, Issels et al. reported the results of a randomized phase 3 trial of neoadjuvant chemotherapy for high-grade STS, which provided considerable evidence supporting neoadjuvant treatment [9] . These investigators concluded that local progression-free survival and diseasefree survival were significantly prolonged by adding hyperthermia to EIA chemotherapy. In their study, the local control rate in the extremity STS subgroup was 92% at 2 years and 89% at 4 years. Nevertheless, while the survival outcomes in the chemotherapy and hyperthermia group were significantly better than those of the chemotherapy alone group, the recurrence rate was inferior to that observed in the present study. The lack of radiotherapy for 40% of patients and different inclusion criteria (Issels et al. included patients who underwent surgery before enrollment and those with non-STS) could explain the differences between the results of the previous randomized study and those of the present study.
The results of a phase 3 randomized trial (the ISG-GEIS trial) suggested the feasibility of neoadjuvant chemotherapy and radiotherapy allowing performance of less invasive surgery [16] . The study authors revealed that combined preoperative chemotherapy and radiotherapy with positive surgical margins yielded a 100%-local control. Likewise, in the present study, the local control rates of patients who underwent RHC were 100%, 94.1%, and 85.7% (wide resection, marginal resection, and intralesional resection, respectively), while the local control rates in the whole BSTT group were 92.2%, 89.8%, and 69.0% (wide resection, marginal resection, and intralesional resection, respectively). This stepwise decrease in the whole BSTT group suggests that tumor invasion around the surgical site and microresidual tumor tissue may be causes of recurrence. However, RHC might eradicate tumor progression around the surgical site, thereby improving the local control rate. Indeed, Matsumoto et al. reported the relationship between margins and the local control rate of infiltrative highly malignant soft tissue tumors in a relatively large population [17] . The local control rates were 90%, 80%, 57%, and 30% (wide margins, inadequate wide margins, marginal resection, and intralesional resection, respectively). These results indicate that neoadjuvant therapy with RHC can downsize tumors, making it possible to achieve closer margins.
No amputations were performed in this study. This might have occurred due to a selective bias in the study inclusion criteria. However, in our experience, to achieve limb preservation, the application of amputation is limited for elderly patients (>70 years), patients with multiple recurrences, and patients with multiple metastases at initial diagnosis. These criteria might not differ from those of other hospitals in Japan. Actually, in our institution, patients who underwent amputation during this study period for STS included patients with multiple recurrences due to unplanned excision (n = 3), patients of advanced age (n = 2), and patients with multifocal lesions due to neurofibromatosis type 1 (n = 1). Moreover, if tumors invaded only major arteries, we preserved the arteries by marginal resection (if the tumor had dramatically shrunk) via reconstruction with an artificial, autograft, or in situ preparation technique [17] . However, this selection bias might have affected the results even after compensation by propensity-matching analysis. Moreover, the second limitation was that the collection of data from the BSTT database was not ideal. Details of neoadjuvant therapy, such as doses or amounts of chemotherapy administered, were unclear. Third, the relatively low number of patients in the RHC group was another limitation. The estimated one-tailed power of this study for comparing the LC between RHC and Figure 8 . Contribution of neoadjuvant therapy to overall survival compared to the RHC group. Each subgroup was extracted from whole BSTT group and trimmed using propensity scores. Hazard ratio was calculated by comparing whole BSTT group and its subgroups with RHC group by log-rank analysis. Figure 9 . Contribution of neoadjuvant therapy to local control compared to the RHC group. Each subgroup was extracted from whole BSTT group and trimmed using propensity scores. Hazard ratio was calculated by comparing whole BSTT group and its subgroups with RHC group by log-rank analysis.
